Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients

Purpose: EGFR and anaplastic lymphoma kinase (ALK) alterations have been regarded as oncogenic drivers and incorporated into clinical practices to manage nonsmall cell lung cancer (NSCLC). Alterations of these two genes were traditionally considered to be mutually exclusive, but recent studies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jixian, Mu, Zhimin, Liu, Li, Li, Kang, Jiang, Richeng, Chen, Peng, Zhou, Qiang, Jin, Meiling, Ma, Yuxiang, Xie, Yuancai, Xiang, Jianxing, Li, Bing, Ma, Yafeng, Mao, Xinru, Zhang, Lu, Zhang, Tengfei, Wu, Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536711/
https://www.ncbi.nlm.nih.gov/pubmed/31213769
http://dx.doi.org/10.2147/DDDT.S196189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536711/
https://www.ncbi.nlm.nih.gov/pubmed/31213769
http://dx.doi.org/10.2147/DDDT.S196189

Ejemplares similares